Cara Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Tvardi Therapeutics

02/08/2024 12:09

* Cara Therapeutics Inc  CARA.OQ   CARA.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 5
(estimated) for the period ending January 1 0001
    * The Stamford Connecticut-based  company is expected to
report a
83.1% decrease in revenue to $1.174 million from $6.93 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Cara Therapeutics Inc is
for a
loss of 27 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $1.01​, above​ its last closing price of $0.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024              -0.40      -0.56     Missed  -40.7
 Dec. 31 2024              -0.41      -0.59     Missed  -43.2
 Sep. 30 2023              -0.52      -0.52     Met     0​
 Jan. 1 0001   -0.53       -0.54      -0.49     Beat    -7.7
 ​​Jan.        -0.51       -0.32      -0.49     Missed  6
 1 0001                                                 
 Dec. 31 2022  -0.35       -0.32      -0.56     Missed  -75​
 Sep. 30 2022  -0.43       -0.42      -0.43     Missed  
 Jan. 1 0001   -0.25       -0.25      -0.08     Beat    68.4
 This summary was machine generated August 2 at 11:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)